Literature DB >> 22215135

Protocols for vaginal inoculation and sample collection in the experimental mouse model of Candida vaginitis.

Junko Yano1, Paul L Fidel.   

Abstract

Vulvovaginal candidiasis (VVC), caused by Candida species, is a fungal infection of the lower female genital tract that affects approximately 75% of otherwise healthy women during their reproductive years. Predisposing factors include antibiotic usage, uncontrolled diabetes and disturbance in reproductive hormone levels due to pregnancy, oral contraceptives or hormone replacement therapies. Recurrent VVC (RVVC), defined as three or more episodes per year, affects a separate 5 to 8% of women with no predisposing factors. An experimental mouse model of VVC has been established and used to study the pathogenesis and mucosal host response to Candida. This model has also been employed to test potential antifungal therapies in vivo. The model requires that the animals be maintained in a state of pseudoestrus for optimal Candida colonization/infection. Under such conditions, inoculated animals will have detectable vaginal fungal burden for weeks to months. Past studies show an extremely high parallel between the animal model and human infection relative to immunological and physiological properties. Differences, however, include a lack of Candida as normal vaginal flora and a neutral vaginal pH in the mice. Here, we demonstrate a series of key methods in the mouse vaginitis model that include vaginal inoculation, rapid collection of vaginal specimens, assessment of vaginal fungal burden, and tissue preparations for cellular extraction/isolation. This is followed by representative results for constituents of vaginal lavage fluid, fungal burden, and draining lymph node leukocyte yields. With the use of anesthetics, lavage samples can be collected at multiple time points on the same mice for longitudinal evaluation of infection/colonization. Furthermore, this model requires no immunosuppressive agents to initiate infection, allowing immunological studies under defined host conditions. Finally, the model and each technique introduced here could potentially give rise to use of the methodologies to examine other infectious diseases of the lower female genital tract (bacterial, parasitic, viral) and respective local or systemic host defenses.

Entities:  

Mesh:

Year:  2011        PMID: 22215135      PMCID: PMC3369659          DOI: 10.3791/3382

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  40 in total

1.  Cell adhesion molecule and lymphocyte activation marker expression during experimental vaginal candidiasis.

Authors:  F L Wormley; J Chaiban; P L Fidel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Effects of reproductive hormones on experimental vaginal candidiasis.

Authors:  P L Fidel; J Cutright; C Steele
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Local Th1/Th2 cytokine production during experimental vaginal candidiasis: potential importance of transforming growth factor-beta.

Authors:  B N Taylor; M Saavedra; P L Fidel
Journal:  Med Mycol       Date:  2000-12       Impact factor: 4.076

4.  Local production of chemokines during experimental vaginal candidiasis.

Authors:  M Saavedra; B Taylor; N Lukacs; P L Fidel
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

5.  Vaginal and oral epithelial cell anti-Candida activity.

Authors:  Fatema Nomanbhoy; Chad Steele; Junko Yano; Paul L Fidel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus.

Authors:  B N Taylor; C Fichtenbaum; M Saavedra; J Slavinsky III; R Swoboda; K Wozniak; A Arribas; W Powderly; P L Fidel
Journal:  J Infect Dis       Date:  2000-08-17       Impact factor: 5.226

7.  A mucosal vaccination approach for herpes simplex virus type 2.

Authors:  Rebecca S Tirabassi; Christopher I Ace; Tatyana Levchenko; Vladimir P Torchilin; Liisa K Selin; Siwei Nie; Dennis L Guberski; Kejian Yang
Journal:  Vaccine       Date:  2010-12-04       Impact factor: 3.641

8.  Increased severity of Candida vaginitis in BALB/c nu/nu mice versus the parent strain is not abrogated by adoptive transfer of T cell enriched lymphocytes.

Authors:  C A Black; F M Eyers; A Russell; M L Dunkley; R L Clancy; K W Beagley
Journal:  J Reprod Immunol       Date:  1999-11       Impact factor: 4.054

9.  NK cells require type I IFN receptor for antiviral responses during genital HSV-2 infection.

Authors:  Navkiran Gill; Meghan J Chenoweth; Elena F Verdu; Ali A Ashkar
Journal:  Cell Immunol       Date:  2011-03-12       Impact factor: 4.868

Review 10.  Distinct protective host defenses against oral and vaginal candidiasis.

Authors:  Paul L Fidel
Journal:  Med Mycol       Date:  2002-08       Impact factor: 4.076

View more
  29 in total

Review 1.  Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework.

Authors:  Mary Ann Jabra-Rizk; Eric F Kong; Christina Tsui; M Hong Nguyen; Cornelius J Clancy; Paul L Fidel; Mairi Noverr
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

2.  Investigation of thiosemicarbazide free or within chitosan nanoparticles in a murine model of vulvovaginal candidiasis.

Authors:  Deize Evangelista Araújo; Amanda Alves de Oliveira; Mirlane Dos Santos Cabral; Adelaide Fernandes Costa; Bárbara Carolina Silva; Lívia do Carmo Silva; Liliana Borges de Menezes; Célia Maria de Almeida Soares; Andre Correa Amaral; Maristela Pereira
Journal:  Braz J Microbiol       Date:  2020-07-08       Impact factor: 2.476

Review 3.  Pathogenesis of Candida albicans biofilm.

Authors:  Christina Tsui; Eric F Kong; Mary Ann Jabra-Rizk
Journal:  Pathog Dis       Date:  2016-06       Impact factor: 3.166

4.  Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal.

Authors:  Akshaya Ravichandran; Jerome Escano; Jung Hwa Lee; Matthew K Ross; Frank Austin; Ravi Orugunty; Shi-En Lu; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

5.  Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis.

Authors:  Brian M Peters; Glen E Palmer; Andrea K Nash; Elizabeth A Lilly; Paul L Fidel; Mairi C Noverr
Journal:  Infect Immun       Date:  2013-11-11       Impact factor: 3.441

6.  Candidalysin Drives Epithelial Signaling, Neutrophil Recruitment, and Immunopathology at the Vaginal Mucosa.

Authors:  Jonathan P Richardson; Hubertine M E Willems; David L Moyes; Saeed Shoaie; Katherine S Barker; Shir Lynn Tan; Glen E Palmer; Bernhard Hube; Julian R Naglik; Brian M Peters
Journal:  Infect Immun       Date:  2018-01-22       Impact factor: 3.441

7.  Comparative Analysis of the Capacity of the Candida Species To Elicit Vaginal Immunopathology.

Authors:  Hubertine M E Willems; David J Lowes; Katherine S Barker; Glen E Palmer; Brian M Peters
Journal:  Infect Immun       Date:  2018-11-20       Impact factor: 3.441

Review 8.  Animal models for candidiasis.

Authors:  Heather R Conti; Anna R Huppler; Natasha Whibley; Sarah L Gaffen
Journal:  Curr Protoc Immunol       Date:  2014-04-02

9.  Exogenous Reproductive Hormones nor Candida albicans Colonization Alter the Near Neutral Mouse Vaginal pH.

Authors:  Jian Miao; Hubertine M E Willems; Brian M Peters
Journal:  Infect Immun       Date:  2021-01-19       Impact factor: 3.441

10.  Antifungal Effect of Long Noncoding RNA 9708-1 in the Vulvovaginal Candidiasis Murine Model.

Authors:  Ying Wu; Lisha Jiang; Lingling Zhang; Xia Liu; Lina Yan; Ting Luan; Can Rui; Zhiyuan Mao; Chong Fan; Yu Liu; Ping Li; Xin Zeng
Journal:  Mycopathologia       Date:  2021-02-15       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.